Abstract
Duchenne muscular dystrophy (DMD) is characterized by the loss of a functional dystrophin protein; the muscles of DMD patients progressively degenerate as a result of mechanical stress during contractions, and the condition eventually leads to premature death. By means antisense oligonucleotides (AONs), it is possible to modulate pre-mRNA splicing eliminating mutated exons and restoring dystrophin open reading frame. To overcome the hurdles in using AONs for therapeutic interventions, we exerted engineered human DMD stem cells with a lentivirus, which permanently and efficiently delivered the cloned AONs. Here we describe for the first time the exosome-mediated release of AONs from engineered human DMD CD133+ stem cells allowing the rescue of murine dystrophin expression. Finally, upon release, AONs could be internalized by host cells suggesting a potential role of exosomes acting as vesicular carriers for DMD gene therapy.
Keywords: Bystander effect, Myogenic stem cells, Delivery of exon skipping machinery.
Current Gene Therapy
Title:Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect
Volume: 15 Issue: 6
Author(s): Mirella Meregalli, Andrea Farini, Clementina Sitzia, Cyriaque Beley, Paola Razini, Letizia Cassinelli, Federica Colleoni, Paola Frattini, Nadia Santo, Elisabetta Galbiati, Davide Prosperi, Alessandro Tavelli, Marzia Belicchi, Luis Garcia and Yvan Torrente
Affiliation:
Keywords: Bystander effect, Myogenic stem cells, Delivery of exon skipping machinery.
Abstract: Duchenne muscular dystrophy (DMD) is characterized by the loss of a functional dystrophin protein; the muscles of DMD patients progressively degenerate as a result of mechanical stress during contractions, and the condition eventually leads to premature death. By means antisense oligonucleotides (AONs), it is possible to modulate pre-mRNA splicing eliminating mutated exons and restoring dystrophin open reading frame. To overcome the hurdles in using AONs for therapeutic interventions, we exerted engineered human DMD stem cells with a lentivirus, which permanently and efficiently delivered the cloned AONs. Here we describe for the first time the exosome-mediated release of AONs from engineered human DMD CD133+ stem cells allowing the rescue of murine dystrophin expression. Finally, upon release, AONs could be internalized by host cells suggesting a potential role of exosomes acting as vesicular carriers for DMD gene therapy.
Export Options
About this article
Cite this article as:
Meregalli Mirella, Farini Andrea, Sitzia Clementina, Beley Cyriaque, Razini Paola, Cassinelli Letizia, Colleoni Federica, Frattini Paola, Santo Nadia, Galbiati Elisabetta, Prosperi Davide, Tavelli Alessandro, Belicchi Marzia, Garcia Luis and Torrente Yvan, Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect, Current Gene Therapy 2015; 15 (6) . https://dx.doi.org/10.2174/1566523215666150929111400
DOI https://dx.doi.org/10.2174/1566523215666150929111400 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Short-Term Intra-Nasal Erythropoietin Administration with Low Sialic Acid Content is without Toxicity or Erythropoietic Effects
Current Neurovascular Research Acetogenin Extracted from <i>Annona muricata</i> Prevented the Actions of EGF in PA-1 Ovarian Cancer Cells
Protein & Peptide Letters The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Synthesis of Silica Based Nanoparticles Against the Proliferation of Human Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Nanopotentiation of Propolis for Revocation of Enzyme Imbalance in UVB Induced Cutaneous Toxicity in Murine Model: a Preliminary Study for Chemoprotection of Skin Cancer
Drug Delivery Letters Patent Selections
Recent Patents on Biomarkers Gene and Cancer Therapy - Pseudorabies Virus: A Novel Research and Therapeutic Tool?
Current Gene Therapy Molecular Mechanisms Underlying St. Johns Wort Drug Interactions
Current Drug Metabolism Naturally Occurring Hydroxytyrosol: Synthesis and Anticancer Potential
Current Medicinal Chemistry The Prognostic Value of Long Non-Coding RNA <i>SNHG7</i> in Human Cancer: A Meta-Analysis
Current Pharmaceutical Biotechnology Big Data to Knowledge: Application of Machine Learning to Predictive Modeling of Therapeutic Response in Cancer
Current Genomics U1 snRNP Control of 3´-End Processing and the Therapeutic Application of U1 Inhibition Combined with RNA Interference
Current Molecular Medicine Topical Targeting Therapies for Sexually Transmitted Diseases
Current Nanoscience Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters Local Recurrence vs Radiotherapy-Induced Edema in Advanced Laryngeal Carcinoma: Is FDG PET/CT Up to the Challenge?
Current Molecular Imaging (Discontinued) Proceedings of the 1<sup>st</sup> Puerto Rico Biobanking Workshop
Reviews on Recent Clinical Trials Depot Based Drug Delivery System for the Management of Depression
Current Drug Delivery Antiviral Compounds Derived from Naturally Occurring Proteins
Current Medicinal Chemistry - Anti-Infective Agents Eosinophils in Cancer: Favourable or Unfavourable?
Current Medicinal Chemistry New Insights into Redox-Modulated Cell Signaling
Current Pharmaceutical Design